1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Gastrointestinal Stromal Tumor (GIST) Drug Revenue
1.4 Market Analysis by Type
1.4.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Amcasertib
1.4.3 Anagrelide hydrochloride CR
1.4.4 APG-1351
1.4.5 Binimetinib
1.4.6 Others
1.5 Market by Application
1.5.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Share by Application: 2021-2026
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Gastrointestinal Stromal Tumor (GIST) Drug Market
1.8.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Manufacturers (2015-2020)
2.3 Global Gastrointestinal Stromal Tumor (GIST) Drug Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Gastrointestinal Stromal Tumor (GIST) Drug Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume Market Share by Region (2015-2020)
3.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Revenue Market Share by Region (2015-2020)
3.3 North America Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume
3.3.1 North America Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume Growth Rate (2015-2020)
3.3.2 North America Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume
3.4.1 East Asia Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume (2015-2020)
3.5.1 Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume Growth Rate (2015-2020)
3.5.2 Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume (2015-2020)
3.6.1 South Asia Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume (2015-2020)
3.7.1 Southeast Asia Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume (2015-2020)
3.8.1 Middle East Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume (2015-2020)
3.9.1 Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume Growth Rate (2015-2020)
3.9.2 Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume (2015-2020)
3.10.1 Oceania Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume (2015-2020)
3.11.1 South America Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume Growth Rate (2015-2020)
3.11.2 South America Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume (2015-2020)
3.12.1 Rest of the World Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America Gastrointestinal Stromal Tumor (GIST) Drug Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Gastrointestinal Stromal Tumor (GIST) Drug Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Gastrointestinal Stromal Tumor (GIST) Drug Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Gastrointestinal Stromal Tumor (GIST) Drug Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Gastrointestinal Stromal Tumor (GIST) Drug Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Gastrointestinal Stromal Tumor (GIST) Drug Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Gastrointestinal Stromal Tumor (GIST) Drug Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Gastrointestinal Stromal Tumor (GIST) Drug Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Gastrointestinal Stromal Tumor (GIST) Drug Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Gastrointestinal Stromal Tumor (GIST) Drug Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Volume Market Share by Type (2015-2020)
14.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Revenue Market Share by Type (2015-2020)
14.3 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Consumption Volume by Application (2015-2020)
15.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in Gastrointestinal Stromal Tumor (GIST) Drug Business
16.1 Ariad Pharmaceuticals, Inc.
16.1.1 Ariad Pharmaceuticals, Inc. Company Profile
16.1.2 Ariad Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Specification
16.1.3 Ariad Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 Chipscreen Biosciences Ltd
16.2.1 Chipscreen Biosciences Ltd Company Profile
16.2.2 Chipscreen Biosciences Ltd Gastrointestinal Stromal Tumor (GIST) Drug Product Specification
16.2.3 Chipscreen Biosciences Ltd Gastrointestinal Stromal Tumor (GIST) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 Astex Pharmaceuticals, Inc.
16.3.1 Astex Pharmaceuticals, Inc. Company Profile
16.3.2 Astex Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Specification
16.3.3 Astex Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 Arog Pharmaceuticals, Inc.
16.4.1 Arog Pharmaceuticals, Inc. Company Profile
16.4.2 Arog Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Specification
16.4.3 Arog Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 Calithera Biosciences, Inc.
16.5.1 Calithera Biosciences, Inc. Company Profile
16.5.2 Calithera Biosciences, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Specification
16.5.3 Calithera Biosciences, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.6 Array BioPharma Inc.
16.6.1 Array BioPharma Inc. Company Profile
16.6.2 Array BioPharma Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Specification
16.6.3 Array BioPharma Inc. Gastrointestinal Stromal Tumor (GIST) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.7 F. Hoffmann-La Roche Ltd.
16.7.1 F. Hoffmann-La Roche Ltd. Company Profile
16.7.2 F. Hoffmann-La Roche Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Product Specification
16.7.3 F. Hoffmann-La Roche Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.8 Boston Biomedical, Inc.
16.8.1 Boston Biomedical, Inc. Company Profile
16.8.2 Boston Biomedical, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Specification
16.8.3 Boston Biomedical, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.9 Blueprint Medicines Corporation
16.9.1 Blueprint Medicines Corporation Company Profile
16.9.2 Blueprint Medicines Corporation Gastrointestinal Stromal Tumor (GIST) Drug Product Specification
16.9.3 Blueprint Medicines Corporation Gastrointestinal Stromal Tumor (GIST) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.10 Deciphera Pharmaceuticals, LLC
16.10.1 Deciphera Pharmaceuticals, LLC Company Profile
16.10.2 Deciphera Pharmaceuticals, LLC Gastrointestinal Stromal Tumor (GIST) Drug Product Specification
16.10.3 Deciphera Pharmaceuticals, LLC Gastrointestinal Stromal Tumor (GIST) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.11 Natco Pharma Limited
16.11.1 Natco Pharma Limited Company Profile
16.11.2 Natco Pharma Limited Gastrointestinal Stromal Tumor (GIST) Drug Product Specification
16.11.3 Natco Pharma Limited Gastrointestinal Stromal Tumor (GIST) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.12 Omeros Corporation
16.12.1 Omeros Corporation Company Profile
16.12.2 Omeros Corporation Gastrointestinal Stromal Tumor (GIST) Drug Product Specification
16.12.3 Omeros Corporation Gastrointestinal Stromal Tumor (GIST) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.13 Horizon Pharma Plc
16.13.1 Horizon Pharma Plc Company Profile
16.13.2 Horizon Pharma Plc Gastrointestinal Stromal Tumor (GIST) Drug Product Specification
16.13.3 Horizon Pharma Plc Gastrointestinal Stromal Tumor (GIST) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.14 Nerviano Medical Sciences S.r.l.
16.14.1 Nerviano Medical Sciences S.r.l. Company Profile
16.14.2 Nerviano Medical Sciences S.r.l. Gastrointestinal Stromal Tumor (GIST) Drug Product Specification
16.14.3 Nerviano Medical Sciences S.r.l. Gastrointestinal Stromal Tumor (GIST) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.15 Kolltan Pharmaceuticals, Inc.
16.15.1 Kolltan Pharmaceuticals, Inc. Company Profile
16.15.2 Kolltan Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Specification
16.15.3 Kolltan Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.16 Immunicum AB
16.16.1 Immunicum AB Company Profile
16.16.2 Immunicum AB Gastrointestinal Stromal Tumor (GIST) Drug Product Specification
16.16.3 Immunicum AB Gastrointestinal Stromal Tumor (GIST) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.17 Novartis AG
16.17.1 Novartis AG Company Profile
16.17.2 Novartis AG Gastrointestinal Stromal Tumor (GIST) Drug Product Specification
16.17.3 Novartis AG Gastrointestinal Stromal Tumor (GIST) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.18 Jiangsu Hengrui Medicine Co., Ltd.
16.18.1 Jiangsu Hengrui Medicine Co., Ltd. Company Profile
16.18.2 Jiangsu Hengrui Medicine Co., Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Product Specification
16.18.3 Jiangsu Hengrui Medicine Co., Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 Gastrointestinal Stromal Tumor (GIST) Drug Manufacturing Cost Analysis
17.1 Gastrointestinal Stromal Tumor (GIST) Drug Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Gastrointestinal Stromal Tumor (GIST) Drug
17.4 Gastrointestinal Stromal Tumor (GIST) Drug Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Gastrointestinal Stromal Tumor (GIST) Drug Distributors List
18.3 Gastrointestinal Stromal Tumor (GIST) Drug Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Gastrointestinal Stromal Tumor (GIST) Drug (2021-2026)
20.2 Global Forecasted Revenue of Gastrointestinal Stromal Tumor (GIST) Drug (2021-2026)
20.3 Global Forecasted Price of Gastrointestinal Stromal Tumor (GIST) Drug (2015-2026)
20.4 Global Forecasted Production of Gastrointestinal Stromal Tumor (GIST) Drug by Region (2021-2026)
20.4.1 North America Gastrointestinal Stromal Tumor (GIST) Drug Production, Revenue Forecast (2021-2026)
20.4.2 East Asia Gastrointestinal Stromal Tumor (GIST) Drug Production, Revenue Forecast (2021-2026)
20.4.3 Europe Gastrointestinal Stromal Tumor (GIST) Drug Production, Revenue Forecast (2021-2026)
20.4.4 South Asia Gastrointestinal Stromal Tumor (GIST) Drug Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia Gastrointestinal Stromal Tumor (GIST) Drug Production, Revenue Forecast (2021-2026)
20.4.6 Middle East Gastrointestinal Stromal Tumor (GIST) Drug Production, Revenue Forecast (2021-2026)
20.4.7 Africa Gastrointestinal Stromal Tumor (GIST) Drug Production, Revenue Forecast (2021-2026)
20.4.8 Oceania Gastrointestinal Stromal Tumor (GIST) Drug Production, Revenue Forecast (2021-2026)
20.4.9 South America Gastrointestinal Stromal Tumor (GIST) Drug Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World Gastrointestinal Stromal Tumor (GIST) Drug Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of Gastrointestinal Stromal Tumor (GIST) Drug by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Gastrointestinal Stromal Tumor (GIST) Drug by Country
21.2 East Asia Market Forecasted Consumption of Gastrointestinal Stromal Tumor (GIST) Drug by Country
21.3 Europe Market Forecasted Consumption of Gastrointestinal Stromal Tumor (GIST) Drug by Countriy
21.4 South Asia Forecasted Consumption of Gastrointestinal Stromal Tumor (GIST) Drug by Country
21.5 Southeast Asia Forecasted Consumption of Gastrointestinal Stromal Tumor (GIST) Drug by Country
21.6 Middle East Forecasted Consumption of Gastrointestinal Stromal Tumor (GIST) Drug by Country
21.7 Africa Forecasted Consumption of Gastrointestinal Stromal Tumor (GIST) Drug by Country
21.8 Oceania Forecasted Consumption of Gastrointestinal Stromal Tumor (GIST) Drug by Country
21.9 South America Forecasted Consumption of Gastrointestinal Stromal Tumor (GIST) Drug by Country
21.10 Rest of the world Forecasted Consumption of Gastrointestinal Stromal Tumor (GIST) Drug by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer